【摘要】 目的 探讨伊沙佐米在多发性骨髓瘤（MM）患者中的应用效果。方法 依据治疗方法的不同将69例MM患者分为对照组（n=34）和观察组（n=35），对照组患者接受来那度胺+地塞米松治疗，观察组患者接受伊沙佐米联合来那度胺+地塞米松治疗。比较两组患者的临床疗效、免疫功能指标（CD4~+、CD8~+、CD4~+/CD8~+）、血清指标[M蛋白、β2-微球蛋白（β2-MG）、红细胞沉降率]及不良反应发生情况。结果 观察组患者的总缓解率为57.14%，高于对照组患者的32.35%，差异有统计学意义（P﹤0.05）。治疗后，两组患者CD4~+水平及CD4~+/CD8~+均高于本组治疗前，CD8~+水平均低于本组治疗前，观察组患者CD4~+水平及CD4~+/CD8~+均高于对照组，CD8~+水平低于对照组，差异均有统计学意义（P﹤0.05）。治疗后，两组患者M蛋白、β2-MG水平及红细胞沉降率均低于本组治疗前，观察组患者M蛋白、β2-MG水平及红细胞沉降率均低于对照组，差异均有统计学意义（P﹤0.05）。观察组患者的不良反应总发生率为31.43%，与对照组患者的41.18%比较，差异无统计学意义（P﹥0.05）。结论 伊沙佐米治疗MM患者可提高总缓解率，改善患者的免疫功能，降低血清指标，且安全性较高。更多还原

【Abstract】 Objective To investigate the application effect of ixazomib in patients with multiple myeloma(MM).Method According to different treatment methods, 69 MM patients were divided into control group(n=34) and observation group(n=35). Patients in the control group received lenalidomide + dexamethasone treatment, while patients in the observation group received ixazomib combind with lenalidomide + dexamethasone treatment. The clinical efficacy, immune function indicators(CD4~+, CD8~+, CD4~+/CD8~+), serum indicators [M protein, β2-microglobulin(β2-MG), erythrocyte sedimentation rate], and incidence of adverse reactions were compared between the two groups. Result The total remission rate in observation group was 57.14%, which was higher than 32.35% in control group, and the difference was statistically significant(P<0.05). After treatment, the levels of CD4~+, CD4~+/CD8~+in both groups were higher than those before treatment, while the levels of CD8~+were lower than those before treatment, the level of CD4~+, and CD4~+/CD8~+in observation group were higher than those in control group, while the level of CD8~+was lower than that in control group, and the differences were statistically significant(P<0.05). After treatment, the levels of M protein, β2-MG and erythrocyte sedimentation rate in both groups were lower than those before treatment, the levels of M protein, β2-MG and erythrocyte sedimentation rate in observation group were lower than those in control group, and the differences were statistically significant(P<0.05). The total incidence of adverse reactions in observation group was 31.43%, which was not statistically significant compared to 41.18% in control group(P>0.05). Conclusion Ixazomib in the treatment of MM patients can improve the overall response rate, enhance the immune function, reduce serum markers, and is relatively safe.更多还原